Opendata, web and dolomites

IM2PACT SIGNED

Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "IM2PACT" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

Organization address
address: WELLINGTON SQUARE UNIVERSITY OFFICES
city: OXFORD
postcode: OX1 2JD
website: www.ox.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 17˙410˙136 €
 EC max contribution 9˙000˙000 € (52%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-12-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) coordinator 2˙462˙486.00
2    UPPSALA UNIVERSITET SE (UPPSALA) participant 1˙113˙250.00
3    AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH AT (WIEN) participant 582˙292.00
4    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 532˙198.00
5    AARHUS UNIVERSITET DK (AARHUS C) participant 483˙966.00
6    UNIVERSITY OF DUNDEE UK (DUNDEE) participant 354˙008.00
7    PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT HU (SZEGED) participant 300˙058.00
8    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 297˙500.00
9    CARDIFF UNIVERSITY UK (CARDIFF) participant 297˙075.00
10    STICHTING VUMC NL (AMSTERDAM) participant 290˙437.00
11    ARTEMIS BIO-SUPPORT B.V. NL (DELFT) participant 290˙380.00
12    STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 290˙312.00
13    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) participant 290˙187.00
14    UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ DE (Mainz) participant 288˙661.00
15    MIMETAS BV NL (Leiden) participant 251˙812.00
16    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 249˙305.00
17    THE OPEN UNIVERSITY UK (MILTON KEYNES) participant 232˙283.00
18    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 213˙718.00
19    NEUWAY PHARMA GMBH DE (BONN) participant 112˙500.00
20    UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA IT (MODENA) participant 67˙565.00
21    FUJIFILM CELLULAR DYNAMICS INC US (MADISON WI) participant 0.00
22    H. LUNDBECK AS DK (VALBY) participant 0.00
23    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
24    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
25    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
26    PFIZER LIMITED UK (SANDWICH) participant 0.00
27    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00

Map

 Project objective

The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery systems, especially for biopharmaceuticals (e.g., peptides, antibodies, etc.) and the identification of novel disease drug targets (Alzheimer’s Disease, MS, metabolic disease). The related key deliverables will be as follows:

1.Identification and validation of specific genes and/or mechanisms which are altered in brain endothelial cells in disease. 2. Generation, validation and characterisation of robust and predictive iPSC-derived BBB models: The developed models should be more reflective of the in vivo situation than existing models, in the healthy and disease states. 3. New, efficacious and safe mechanisms and technologies of brain delivery: The output of this topic should also result in an expanded and deepened understanding of the fundamental processes that underpin drug-trafficking across the BBB, which in turn can further support endeavours to elucidate novel and more efficacious brain delivery mechanisms. 4. Characterised new genetic models for the diseases of interest in this topic which are better amenable to evaluate disease-modifying agents. 5. Characterised mechanisms of neurotropic virus-mediated BBB and CNS penetration for development of selective brain delivery systems. 6. Established in silico/mathematical models in predicting BBB penetration of therapeutics (such as receptor-or carrier-mediated transcytosis for delivery across the BBB) and pharmacokinetics of biopharmaceutics in different compartments of CNS. 7. Identification of relevant translational readouts which are better amenable to elucidate the role of the BBB in the pathogenesis of neurodegeneration and could eventually lead to new targets for the treatment of the neurovascular causes of the diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IM2PACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IM2PACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More